Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06075693 · ClinicalTrials.gov registry record
Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy
A clinical trial of Myotonic Dystrophy Type 1, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 88
- Enrollment target
- 1
- Study location
NCT06075693: Recruiting study of Myotonic Dystrophy Type 1, sponsored by Massachusetts General Hospital.
NCT06075693 is a study of Myotonic Dystrophy Type 1 that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 88 participants, below the 1,056-participant average among 3 other Myotonic Dystrophy Type 1 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06075693, a study of Myotonic Dystrophy Type 1, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 88 participants
- Enrollment target
- 1
- Study location
Study Summary
Myotonic dystrophy is associated with central sleep apnea, excessive daytime sleepiness, diminished working memory, impaired visuospatial skills, and deficits in problem-solving skills. Cerebrospinal fluid (CSF) is a clear, colorless fluid that surrounds and protects the brain. Changes in the composition of CSF can serve as early indicators of changes in brain activity and function. The purpose of this research is to learn about myotonic dystrophy by examining cerebrospinal fluid and brain activity in participants. The tests will be low risk and are well tolerated. The information that we gather from this study may help us evaluate, prevent, diagnose, treat, and improve our understanding of myotonic dystrophy. Funding Source- FDA OOPD
Primary Outcome
The extracellular RNA biomarkers in the muscular dystrophy groups will be evaluated and compared with the extracellular RNA content in control groups. Statistical analysis will be used to evaluate the sensitivity and specificity of these markers as measurements of disease activity and severity.
Conditions Studied
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2028-08-01 |
What NCT06075693 shows while recruiting
NCT06075693 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 1,056-participant average among 3 other Myotonic Dystrophy Type 1 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Myotonic Dystrophy Type 1 appearing as the primary indexed condition, and to 0 interventions.
NCT06075693 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06075693 about?
NCT06075693 is a clinical study titled "Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy". Myotonic dystrophy is associated with central sleep apnea, excessive daytime sleepiness, diminished working memory, impaired visuospatial skills, and deficits in problem-solving skills. Cerebrospinal fluid (CSF) is a clear, colorless fluid that surrounds and protects the brain. Changes in the comp...
What is the current status of trial NCT06075693?
This trial is currently recruiting. The enrollment target is 88 participants. The study started on 2022-08-01. Estimated completion is 2028-08-01.
What conditions does trial NCT06075693 study?
This clinical trial studies the following conditions: Myotonic Dystrophy Type 1.
Who is sponsoring clinical trial NCT06075693?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06075693 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myotonic Dystrophy Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2
RECRUITING
-
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
RECRUITING
-
Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI